高级搜索

应用磁珠联合质谱技术建立结直肠癌血清差异蛋白诊断模型

刘清银, 李明, 涂斌, 胡晓丹, 孙良起, 李华信

刘清银, 李明, 涂斌, 胡晓丹, 孙良起, 李华信. 应用磁珠联合质谱技术建立结直肠癌血清差异蛋白诊断模型[J]. 肿瘤防治研究, 2015, 42(08): 801-805. DOI: 10.3971/j.issn.1000-8578.2015.08.011
引用本文: 刘清银, 李明, 涂斌, 胡晓丹, 孙良起, 李华信. 应用磁珠联合质谱技术建立结直肠癌血清差异蛋白诊断模型[J]. 肿瘤防治研究, 2015, 42(08): 801-805. DOI: 10.3971/j.issn.1000-8578.2015.08.011
shu
LIU Qingyin, LI Ming, TU Bin, HU Xiaodan, SUN Liangqi, LI Huaxin. Serum Peptidome Patterns of Colorectal Cancer Based on Magnetic Bead Separation and Mass-spectrometry Technique[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 801-805. DOI: 10.3971/j.issn.1000-8578.2015.08.011
Citation: LIU Qingyin, LI Ming, TU Bin, HU Xiaodan, SUN Liangqi, LI Huaxin. Serum Peptidome Patterns of Colorectal Cancer Based on Magnetic Bead Separation and Mass-spectrometry Technique[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 801-805. DOI: 10.3971/j.issn.1000-8578.2015.08.011
shu

应用磁珠联合质谱技术建立结直肠癌血清差异蛋白诊断模型

  • 1. 471031 洛阳，中国人民解放军第150中心医院检验科；2. 471031 洛阳，中国人民解放军第150中心医院呼吸科；3. 471003 洛阳，洛阳市海关出入境检验检疫局检验科；4. 471031 洛阳，中国人民解放军第150中心医院输血科

详细信息
    作者简介:

    刘清银（1979-），女，学士，主管技师，主要从事免疫学临床诊断以及消化系肿瘤的早期诊断研究

    通讯作者:

    孙良起，E-mail: slq6311@sohu.com

    李华信，E-mail: 947273373@qq.com

  • 中图分类号: R454.1；R735.3；R44

Serum Peptidome Patterns of Colorectal Cancer Based on Magnetic Bead Separation and Mass-spectrometry Technique

  • 1. Clinical Laboratory, The 150th Hospital of Chinese PLA, Luoyang 471031, China; 2.Department of Respiration, The 150th Hospital of Chinese PLA, Luoyang 471031, China;3. Import and Export Inspection and Quarantine Division, Luoyang 471003, China; 4.Department of Transfusion, The 150 th Hospital of Chinese PLA, Luoyang 471031, China

HTML全文

    摘要
  • 摘要: 目的 应用磁珠联合质谱技术筛选结直肠癌Ⅰ、Ⅱ期患者差异蛋白质，建立其血清学筛查方法。方法 收集血清样本156例（其中结直肠癌80例，健康志愿者76例），随机分为建模组和验证组。采用弱阳离子磁珠分离血清小分子蛋白，基质辅助激光解吸离子飞行时间质谱仪建立结直肠癌及健康志愿者血清蛋白谱，Clinprot Tools 2.2软件对建模组血清蛋白谱进行定量分析，建立结直肠癌判别模型，以所获取的判别模型判别验证组样本，评价判别模型的诊断价值。应用ELISA法检测验证组癌胚抗原。结果 对比分析建模组结直肠癌及健康志愿者血清蛋白谱，发现共有44个差异蛋白峰（P<0.05），其中在结直肠癌中高表达35个，低表达9个，利用其中3个差异峰（质荷比分别为1330.95、2883.96、9294.14）建立诊断模型，交叉验证的准确性为94.87%（74/78），经独立样本双盲验证，其敏感度为87.50%（35/40），特异性为89.47%（34/38），高于CEA。结论 应用磁珠分离和质谱技术建立的诊断模型具有较高的准确性，对提高结直肠癌的筛查具有一定的临床意义。

     

    Abstract: Objective To establish a proteomic pattern for colorectal cancer(CRC) screening by comparing serum proteomic spectra between CRCs and healthy individuals. Methods Serum samples were collected from 80 CRCs and 78 healthy volunteers, and randomly divided into model construction group and validation group. The weak cation exchange(WCX) beads combined matrix-assisted laser desorption/ionization time of flight mass spectrometry(MALDI-TOF MS) technique were used to detect the mass spectrometry data. The obtained mass spectrometry data were then analyzed using Clinprot Tools 2.2 software. A model identifying CRC from healthy volunteers was built in the model construction group and evaluated in the model validation group for reliability. Serum CEA from validation group was detected using ELISA kit as a control. Results Forty-four differentially expressed proteins in serum(P<0.05), including 35 up-regulated proteins and 9 down-regulated proteins, were screened by comparing serum protemic spectra between CRCs and healthy volunteers. Three proteins at m/z 1330.95, 2883.96 and 9294.14 were obtained for developing a Clinprot model which could identify CRCs from healthy volunteers with an accuracy of 94.87%(74/78). In a double blind validation, the Clinprot model yielded a sensitivity of 87.50% and a specificity of 89.47%, which surpassed to CEA. Conclusion Clinprot model constructed using MALDI-TOF-MS combined with WCX kit technology allows identifying CRCs from healthy volunteers with high accuracy, which may contribute to the screening of CRCs.

     

    • HTML全文
    • 参考文献(20)
  • [1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
    [2] Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening[J]. CA Cancer J Clin， 20 11, 61(1): 8-30.
    [3] Cho WC. Contribution of oncoproteomics to cancer biomarker discovery[J]. Mol Cancer, 2007, 6: 25.
    [4] Martinez-Aguilar J, Chik J, Nicholson J, et al. Quantitative mass spectrometry for colorectal cancer proteomics[J]. Proteomics Clin Appl, 2013, 7(1-2): 42-54.
    [5] Ikonomou G, Samiotaki M, Panayotou G. Proteomic methodologies and their application in colorectal cancer research[J]. Crit Rev Clin Lab Sci, 2009, 46(5-6): 319-42.
    [6] Fan NJ, Gao CF, Zhao G, et al. Serum peptidome patterns for early screening of esophageal squamous cell carcinoma[J]. Biotechnol Appl Biochem, 2012, 59(4): 276-82.
    [7] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
    [8] Ang CS, Phung J, Nice EC. The discovery and validation of colorectal cancer biomarkers[J]. Biomed Chromatogr, 2011, 25 (1-2): 82-99.
    [9] Makridakis M, Vlahou A. Secretome proteomics for discovery of cancer biomarkers[J]. J Proteomics, 2010, 73(12): 2291-305.
    [10] Ahlquist DA. Molecular detection of colorectal neoplasia[J]. Gastroenterology, 2010, 138(6): 2127-39.
    [11] Fan NJ, Li K, Liu QY, et al. Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b-c complex subunit 1 as serological diagnostic biomarkers of gastric cancer[J]. Clin Biochem, 2013(46): 1578-84.
    [12] Fan NJ, Gao CF, Wang XL. Identification of regional lymph node involvement of colorectal cancer by serum SELDI proteomic patterns[J]. Gastroenterol Res Pract, 2011, 2011: 784967.
    [13] Ghafourian S, Sekawi Z, Raftari M, et al. Application of proteomics in lab diagnosis[J]. Clin Lab, 2013, 59(5-6): 465-74.
    [14] Martinez-Aguilar J, Molloy MP. Label-free selected reaction monitoring enables multiplexed quantitation of S100 protein isoforms in cancer cells[J]. J Proteome Res, 2013, 12(8): 3679-88.
    [15] Fan NJ, Gao CF, Wang XL. Tubulin beta chain, filamin a Alpha Iisoform 1, and cytochrome b-c1 complex subunit 1 as serological diagnostic biomarkers of esophageal squamous cell carcinoma: a proteomics study[J]. OMICS, 2013, 17(4): 215-23.
    [16] Fan NJ, Gao CF, Zhao G, et al. Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis[J]. Diagn Pathol, 2012, 7: 45.
    [17] Tang W, Shi YQ, Zou JJ, et al. Serum biomarker of diabetic peripheral neuropathy indentified by differential proteomics[J]. Front Biosci(Landmark Ed), 2011, 16: 2671-81.
    [18] Dai Y, Hu C, Wang L, et al. Serum peptidome patterns of human systemic lupus erythematosus based on magnetic bead separation and MALDI-TOF mass spectrometry analysis[J]. Scand J Rheumatol, 2010, 39(3): 240-6.
    [19] Fan NJ, Gao CF, Wang XL, et al. Serum peptidome patterns of colorectal cancer based on magnetic bead separation and MALDITOF mass spectrometry analysis[J]. Biomed Biotechnol, 2012, 20 12: 985020.
    [20] Fan NJ, Kang R, Ge XY, et al. Identification alpha-2-HSglycoprotein precursor and tubulin beta chain as serology diagnosis biomarker of colorectal cancer[J]. Diagn Pathol, 2014, 9: 53.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1183
  • HTML全文浏览量:  311
  • PDF下载量:  356
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-10-16
  • 修回日期:  2015-01-17
  • 刊出日期:  2015-08-24

目录

摘要
HTML全文
    参考文献(20)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：11648775 今日访问：16124

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭